These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223 [TBL] [Abstract][Full Text] [Related]
3. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD MAbs; 2015; 7(1):84-95. PubMed ID: 25524268 [TBL] [Abstract][Full Text] [Related]
4. Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF. Wang S; Liu M; Zeng D; Qiu W; Ma P; Yu Y; Chang H; Sun Z Proteins; 2014 Oct; 82(10):2620-30. PubMed ID: 24916692 [TBL] [Abstract][Full Text] [Related]
5. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473 [TBL] [Abstract][Full Text] [Related]
6. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity. Kumar S; Roffi K; Tomar DS; Cirelli D; Luksha N; Meyer D; Mitchell J; Allen MJ; Li L Protein Eng Des Sel; 2018 Jul; 31(7-8):313-325. PubMed ID: 30189027 [TBL] [Abstract][Full Text] [Related]
7. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity. Shen Y; Zeng L; Zhu A; Blanc T; Patel D; Pennello A; Bari A; Ng S; Persaud K; Kang YK; Balderes P; Surguladze D; Hindi S; Zhou Q; Ludwig DL; Snavely M MAbs; 2013; 5(3):418-31. PubMed ID: 23567210 [TBL] [Abstract][Full Text] [Related]
8. Stability engineering of the human antibody repertoire. Rouet R; Lowe D; Christ D FEBS Lett; 2014 Jan; 588(2):269-77. PubMed ID: 24291820 [TBL] [Abstract][Full Text] [Related]
9. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. Goldberg DS; Bishop SM; Shah AU; Sathish HA J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568 [TBL] [Abstract][Full Text] [Related]
10. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L MAbs; 2020; 12(1):1743053. PubMed ID: 32249670 [TBL] [Abstract][Full Text] [Related]
11. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR MAbs; 2020; 12(1):1787121. PubMed ID: 32658605 [TBL] [Abstract][Full Text] [Related]
12. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. Geoghegan JC; Fleming R; Damschroder M; Bishop SM; Sathish HA; Esfandiary R MAbs; 2016 Jul; 8(5):941-50. PubMed ID: 27050875 [TBL] [Abstract][Full Text] [Related]
13. N-terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains. Gibson SJ; Bond NJ; Milne S; Lewis A; Sheriff A; Pettman G; Pradhan R; Higazi DR; Hatton D Biotechnol Bioeng; 2017 Sep; 114(9):1970-1977. PubMed ID: 28369727 [TBL] [Abstract][Full Text] [Related]
14. A novel screening method to assess developability of antibody-like molecules. Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA MAbs; 2015; 7(4):752-8. PubMed ID: 25961854 [TBL] [Abstract][Full Text] [Related]
15. Pragmatic mAb lead molecule engineering from a developability perspective. Chi B; De Oliveira G; Gallagher T; Mitchell L; Knightley L; Gonzalez CC; Russell S; Germaschewski V; Pearce C; Sellick CA Biotechnol Bioeng; 2021 Oct; 118(10):3733-3743. PubMed ID: 33913507 [TBL] [Abstract][Full Text] [Related]
16. Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability. Bashour H; Smorodina E; Pariset M; Zhong J; Akbar R; Chernigovskaya M; Lê Quý K; Snapkow I; Rawat P; Krawczyk K; Sandve GK; Gutierrez-Marcos J; Gutierrez DN; Andersen JT; Greiff V Commun Biol; 2024 Jul; 7(1):922. PubMed ID: 39085379 [TBL] [Abstract][Full Text] [Related]
17. Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies: Differential Scanning Calorimetry, Isothermal Chemical Denaturation, and Intrinsic Fluorescence with Concomitant Static Light Scattering. Temel DB; Landsman P; Brader ML Methods Enzymol; 2016; 567():359-89. PubMed ID: 26794361 [TBL] [Abstract][Full Text] [Related]
18. Modification of the kinetic stability of immunoglobulin G by solvent additives. Schaefer JV; Sedlák E; Kast F; Nemergut M; Plückthun A MAbs; 2018; 10(4):607-623. PubMed ID: 29537925 [TBL] [Abstract][Full Text] [Related]
19. An accelerated surface-mediated stress assay of antibody instability for developability studies. Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P MAbs; 2020; 12(1):1815995. PubMed ID: 32954930 [TBL] [Abstract][Full Text] [Related]
20. A general approach to antibody thermostabilization. McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]